About Poniard Pharmaecuticals (OTCMKTS:PARD)
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
Poniard Pharmaecuticals (OTCMKTS:PARD) Frequently Asked Questions
What is Poniard Pharmaecuticals' stock symbol?
Poniard Pharmaecuticals trades on the OTCMKTS under the ticker symbol "PARD."
Who are some of Poniard Pharmaecuticals' key competitors?
Who are Poniard Pharmaecuticals' key executives?
Poniard Pharmaecuticals' management team includes the folowing people:
- Ronald A. Martell, Chairman of the Board (Age 54)
- Robert S. Basso, Independent Director (Age 67)
- Frederick B. Craves Ph.D., Independent Director (Age 70)
- Carl S. Goldfischer M.D., Independent Director (Age 58)
- Robert M. Littauer, Independent Director (Age 56)
- David R. Stevens Ph.D., Independent Director (Age 67)
Has Poniard Pharmaecuticals been receiving favorable news coverage?
Media headlines about PARD stock have been trending positive on Thursday, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Poniard Pharmaecuticals earned a media sentiment score of 0.27 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 46.74 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Poniard Pharmaecuticals?
Shares of PARD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Poniard Pharmaecuticals' stock price today?
One share of PARD stock can currently be purchased for approximately $0.0470.
How big of a company is Poniard Pharmaecuticals?
Poniard Pharmaecuticals has a market capitalization of $70,000.00.
How can I contact Poniard Pharmaecuticals?
Poniard Pharmaecuticals' mailing address is 750 BATTERY STREET SUITE 330, SAN FRANCISCO CA, 98119-4114. The biopharmaceutical company can be reached via phone at 206-286-2501 or via email at [email protected]
MarketBeat Community Rating for Poniard Pharmaecuticals (PARD)MarketBeat's community ratings are surveys of what our community members think about Poniard Pharmaecuticals and other stocks. Vote "Outperform" if you believe PARD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PARD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Poniard Pharmaecuticals (OTCMKTS:PARD) Analyst Ratings History
(Data available from 4/26/2016 forward)
Poniard Pharmaecuticals (OTCMKTS:PARD) Earnings History and Estimates Chart
Poniard Pharmaecuticals (OTCMKTS PARD) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Poniard Pharmaecuticals (OTCMKTS:PARD) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Poniard Pharmaecuticals (OTCMKTS PARD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 30.00%
Poniard Pharmaecuticals (OTCMKTS PARD) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Poniard Pharmaecuticals (OTCMKTS PARD) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Poniard Pharmaecuticals (OTCMKTS:PARD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Poniard Pharmaecuticals (OTCMKTS:PARD) Income Statement, Balance Sheet and Cash Flow Statement
Poniard Pharmaecuticals (OTCMKTS PARD) Stock Chart for Thursday, April, 26, 2018